D.Western Therapeutics Institute (6DW) Ratios
D.Western Therapeutics Institute Ratios
DE:6DW's free cash flow for Q1 2026 was $0.00. For the 2026 fiscal year, DE:6DW's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.91 | 11.12 | 11.02 | 12.59 | 11.19 |
| Quick Ratio | 9.48 | 10.35 | 10.57 | 12.21 | 10.73 |
| Cash Ratio | 8.39 | 8.49 | 9.62 | 11.05 | 10.01 |
| Solvency Ratio | -0.80 | -1.33 | -0.70 | -0.35 | -0.24 |
| Operating Cash Flow Ratio | -2.42 | -9.79 | -3.02 | -1.68 | -0.91 |
| Short-Term Operating Cash Flow Coverage | -4.99 | -68.20 | -61.61 | -2.96 | -1.36 |
| Net Current Asset Value | $ 1.29B | $ 539.81M | $ 1.04B | $ 1.58B | $ 1.73B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.28 | 0.48 | 0.37 | 0.33 | 0.14 |
| Debt-to-Equity Ratio | 0.42 | 1.09 | 0.69 | 0.52 | 0.17 |
| Debt-to-Capital Ratio | 0.30 | 0.52 | 0.41 | 0.34 | 0.14 |
| Long-Term Debt-to-Capital Ratio | 0.26 | 0.51 | 0.41 | 0.31 | 0.09 |
| Financial Leverage Ratio | 1.51 | 2.27 | 1.85 | 1.59 | 1.23 |
| Debt Service Coverage Ratio | -5.32 | -50.94 | -64.69 | -3.19 | -0.83 |
| Interest Coverage Ratio | -70.32 | -232.17 | -320.71 | -97.21 | -38.80 |
| Debt to Market Cap | 0.13 | 0.11 | 0.20 | 0.12 | 0.05 |
| Interest Debt Per Share | 12.81 | 22.87 | 27.93 | 32.75 | 11.74 |
| Net Debt to EBITDA | 1.93 | 0.27 | 1.27 | 3.50 | 14.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 77.72% | 90.07% | 91.44% | 93.85% | 95.15% |
| EBIT Margin | -159.92% | -272.17% | -192.43% | -97.55% | -37.47% |
| EBITDA Margin | -147.66% | -261.71% | -181.06% | -87.20% | -26.55% |
| Operating Profit Margin | -159.92% | -256.50% | -186.42% | -68.27% | -41.42% |
| Pretax Profit Margin | -162.66% | -273.27% | -193.01% | -98.25% | -38.54% |
| Net Profit Margin | -163.07% | -273.61% | -189.65% | -95.89% | -35.95% |
| Continuous Operations Profit Margin | -163.07% | -273.61% | -193.39% | -98.61% | -38.92% |
| Net Income Per EBT | 100.25% | 100.12% | 98.26% | 97.60% | 93.29% |
| EBT Per EBIT | 101.71% | 106.54% | 103.54% | 143.92% | 93.05% |
| Return on Assets (ROA) | -29.14% | -77.29% | -34.23% | -14.53% | -6.05% |
| Return on Equity (ROE) | -44.03% | -175.82% | -63.48% | -23.13% | -7.42% |
| Return on Capital Employed (ROCE) | -31.54% | -78.71% | -36.64% | -11.14% | -7.56% |
| Return on Invested Capital (ROIC) | -30.02% | -77.75% | -36.48% | -10.68% | -7.15% |
| Return on Tangible Assets | -29.17% | -79.40% | -35.53% | -15.17% | -6.49% |
| Earnings Yield | -13.74% | -18.28% | -18.13% | -5.53% | -2.35% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.10 | 3.77 | 3.66 | 2.62 | 4.08 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.99 | 0.46 | 0.42 | 0.35 | 0.23 |
| Fixed Asset Turnover | 42.04 | 42.14 | 42.79 | 44.34 | 90.74 |
| Asset Turnover | 0.18 | 0.28 | 0.18 | 0.15 | 0.17 |
| Working Capital Turnover Ratio | 0.25 | 0.29 | 0.20 | 0.20 | 0.19 |
| Cash Conversion Cycle | 456.28 | 891.25 | 974.47 | 1187.92 | 1694.88 |
| Days of Sales Outstanding | 88.99 | 96.77 | 99.82 | 139.09 | 89.55 |
| Days of Inventory Outstanding | 367.29 | 794.48 | 874.65 | 1048.83 | 1605.34 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 456.28 | 891.25 | 974.47 | 1187.92 | 1694.88 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -10.30 | -36.99 | -18.47 | -11.97 | -6.01 |
| Free Cash Flow Per Share | -10.36 | -37.25 | -18.94 | -12.30 | -6.11 |
| Dividend Paid and CapEx Coverage Ratio | -179.89 | -143.95 | -39.28 | -36.15 | -60.82 |
| Capital Expenditure Coverage Ratio | -179.89 | -143.95 | -39.28 | -36.15 | -60.82 |
| Operating Cash Flow Coverage Ratio | -0.82 | -1.63 | -0.66 | -0.37 | -0.52 |
| Operating Cash Flow to Sales Ratio | -1.27 | -2.75 | -1.37 | -0.79 | -0.43 |
| Free Cash Flow Yield | -10.79% | -18.53% | -13.43% | -4.69% | -2.83% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.28 | -5.47 | -5.52 | -18.07 | -42.53 |
| Price-to-Sales (P/S) Ratio | 11.87 | 14.97 | 10.46 | 17.33 | 15.29 |
| Price-to-Book (P/B) Ratio | 3.21 | 9.62 | 3.50 | 4.18 | 3.16 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.27 | -5.40 | -7.45 | -21.30 | -35.36 |
| Price-to-Operating Cash Flow Ratio | -9.32 | -5.43 | -7.64 | -21.89 | -35.94 |
| Price-to-Earnings Growth (PEG) Ratio | 0.11 | -0.13 | -0.07 | -0.10 | 0.85 |
| Enterprise Value Multiple | -6.11 | -5.45 | -4.51 | -16.38 | -43.10 |
| Enterprise Value | 3.50B | 6.73B | 3.50B | 6.40B | 4.74B |
| EV to EBITDA | -6.11 | -5.45 | -4.51 | -16.38 | -43.10 |
| EV to Sales | 9.02 | 14.27 | 8.17 | 14.28 | 11.44 |
| EV to Free Cash Flow | -7.04 | -5.15 | -5.81 | -17.55 | -26.46 |
| EV to Operating Cash Flow | -7.08 | -5.18 | -5.96 | -18.04 | -26.90 |
| Tangible Book Value Per Share | 29.90 | 19.63 | 37.55 | 59.01 | 63.70 |
| Shareholders’ Equity Per Share | 29.95 | 20.90 | 40.27 | 62.67 | 68.42 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
| Revenue Per Share | 8.09 | 13.43 | 13.48 | 15.12 | 14.13 |
| Net Income Per Share | -13.19 | -36.74 | -25.56 | -14.50 | -5.08 |
| Tax Burden | 1.00 | 1.00 | 0.98 | 0.98 | 0.93 |
| Interest Burden | 1.02 | 1.00 | 1.00 | 1.01 | 1.03 |
| Research & Development to Revenue | 1.73 | 2.90 | 2.17 | 1.05 | 0.76 |
| SG&A to Revenue | 0.65 | 0.56 | 0.25 | 0.23 | 0.27 |
| Stock-Based Compensation to Revenue | 0.00 | 0.04 | 0.04 | 0.00 | 0.00 |
| Income Quality | 0.78 | 1.01 | 0.72 | 1.75 | 1.10 |
Currency in JPY
